http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-95251-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_382ccfc2ebebcaee15aa7cda4cee86bc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate | 2006-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da797139c6be738232df60d2ba9aef73 |
| publicationDate | 2011-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | UA-95251-C2 |
| titleOfInvention | PHARMACEUTICAL COMPOSITION CONTAINING 2,3-DIGIDRO-6-NITROIMIDASO [2,1-b] OXAZOLE DERIVATIVES |
| abstract | The pharmaceutical composition of the present invention comprises: (I) at least one compound selected from the group consisting of oxazole compounds, their optically active isomers and their salts, the oxazole compounds being represented by the general formula (1): (1) wherein R is an atom hydrogen or alkyl group; n is an integer from 0 to 6, and R denotes, for example, a group of General formula (A), presented below: (A) where R denotes a phenoxy group optionally substituted on the phenyl ring by one or more substituents selected from the group consisting of of halogen atoms, halogen-substituted or unsubstituted alkyl groups and halogen-substituted or unsubstituted Salkoxy groups; and (II) at least one cellulose compound selected from the group consisting of hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose succinate acetate.This pharmaceutical composition has improved solubility of the oxazole compound in water. selected from the group consisting of oxazole compounds, their optically active isomers and their salts, the oxazole compounds being represented by the general formula (1) :, (1) wherein R is a hydrogen atom or a C 1-4 alkyl group; n is an integer from 0 to 6, and R is, for example, a group of general formula (A) as follows: (A) wherein R is a phenoxy group optionally substituted on the phenyl ring by one or more substituents selected from the group consisting of atoms halogen, halogen-substituted or unsubstituted alkyl groups and halogen-substituted or unsubstituted Salkoxy groups; and (II) at least one cellulose compound selected from |
| priorityDate | 2005-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.